True North Advisors’s DexCom DXCM Stock Holding History

True North Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,000	Closed	-$810K	–	191
2020 Q2	$810K	Sell	8,000 -84	-1%	-$7.51K	0.19%	87
2020 Q1	$544K	Buy	+8,084	New	+$503K	0.19%	68

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

True North Advisors's DXCM Position: Q3 2020 in Review

True North Advisors sold out of DexCom (DXCM) in Q3 2020, closing a stake of 8,000 shares — an estimated $810K sold.

True North Advisors first reported a position in DXCM in Q1 2020 and held it in 2 quarters. The position peaked at $810K in Q2 2020. 727 funds tracked by Wall St. Rank hold DXCM as of Q3 2020.

True North Advisors reported no remaining DexCom position as of Q3 2020 after selling out during the quarter.
True North Advisors sold 8,000 DexCom shares in Q3 2020, an estimated $810K.
True North Advisors first reported a position in DexCom in Q1 2020 and held it in 2 quarters.
True North Advisors's DexCom position peaked at $810K in Q2 2020.
727 funds tracked by Wall St. Rank held DexCom as of Q3 2020.

Based on True North Advisors's 13F filing for Q3 2020, filed 20 May 2022.